Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Abstract Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials comparing the outcomes of backbone t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Szabolcs Kiss, Noémi Gede, Péter Hegyi, Bettina Nagy, Rita Deák, Fanni Dembrovszky, Stefania Bunduc, Bálint Erőss, Tamás Leiner, Zsolt Szakács, Hussain Alizadeh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bb89688f4cc1490991d590005ba1fb34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb89688f4cc1490991d590005ba1fb34
record_format	dspace
spelling	oai:doaj.org-article:bb89688f4cc1490991d590005ba1fb342021-11-14T12:21:16ZAddition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials10.1038/s41598-021-01440-x2045-2322https://doaj.org/article/bb89688f4cc1490991d590005ba1fb342021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01440-xhttps://doaj.org/toc/2045-2322Abstract Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials comparing the outcomes of backbone therapy with and without daratumumab in relapsed/refractory and newly diagnosed myeloma (RRMM and NDMM, respectively). Odds ratios (ORs) and hazard ratios (HRs) were calculated with 95% confidence intervals (CIs). Primary outcomes were death or disease progression, minimal residual disease (MRD) negativity, and stringent complete response (sCR). Secondary outcomes were complete response or better and safety endpoints prespecified in the study protocol: PROSPERO (CRD42020222904). In NDMM, MRD negativity [OR = 3.61 (CI 2.33–5.61)] and sCR [OR = 2.29 (CI 1.49–3.51)] were more likely and death or disease progression [HR = 0.47 (CI 0.39–0.57)] was less likely to occur with daratumumab compared to control. Regarding RRMM, MRD negativity [OR = 5.43 (CI 2.76–10.66)] and sCR [OR = 3.08 (CI 2.00–4.76)] were more likely and death or disease progression was less likely [HR = 0.50 (CI 0.37–0.67)] with daratumumab compared to control. The addition of daratumumab has shown high clinical efficacy and acceptable toxicity profile for the treatment of NDMM and RRMM regarding the endpoints examined.Szabolcs KissNoémi GedePéter HegyiBettina NagyRita DeákFanni DembrovszkyStefania BunducBálint ErőssTamás LeinerZsolt SzakácsHussain AlizadehNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Szabolcs Kiss Noémi Gede Péter Hegyi Bettina Nagy Rita Deák Fanni Dembrovszky Stefania Bunduc Bálint Erőss Tamás Leiner Zsolt Szakács Hussain Alizadeh Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
description	Abstract Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials comparing the outcomes of backbone therapy with and without daratumumab in relapsed/refractory and newly diagnosed myeloma (RRMM and NDMM, respectively). Odds ratios (ORs) and hazard ratios (HRs) were calculated with 95% confidence intervals (CIs). Primary outcomes were death or disease progression, minimal residual disease (MRD) negativity, and stringent complete response (sCR). Secondary outcomes were complete response or better and safety endpoints prespecified in the study protocol: PROSPERO (CRD42020222904). In NDMM, MRD negativity [OR = 3.61 (CI 2.33–5.61)] and sCR [OR = 2.29 (CI 1.49–3.51)] were more likely and death or disease progression [HR = 0.47 (CI 0.39–0.57)] was less likely to occur with daratumumab compared to control. Regarding RRMM, MRD negativity [OR = 5.43 (CI 2.76–10.66)] and sCR [OR = 3.08 (CI 2.00–4.76)] were more likely and death or disease progression was less likely [HR = 0.50 (CI 0.37–0.67)] with daratumumab compared to control. The addition of daratumumab has shown high clinical efficacy and acceptable toxicity profile for the treatment of NDMM and RRMM regarding the endpoints examined.
format	article
author	Szabolcs Kiss Noémi Gede Péter Hegyi Bettina Nagy Rita Deák Fanni Dembrovszky Stefania Bunduc Bálint Erőss Tamás Leiner Zsolt Szakács Hussain Alizadeh
author_facet	Szabolcs Kiss Noémi Gede Péter Hegyi Bettina Nagy Rita Deák Fanni Dembrovszky Stefania Bunduc Bálint Erőss Tamás Leiner Zsolt Szakács Hussain Alizadeh
author_sort	Szabolcs Kiss
title	Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
title_short	Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
title_full	Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
title_fullStr	Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
title_full_unstemmed	Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
title_sort	addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bb89688f4cc1490991d590005ba1fb34
work_keys_str_mv	AT szabolcskiss additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT noemigede additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT peterhegyi additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT bettinanagy additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT ritadeak additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT fannidembrovszky additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT stefaniabunduc additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT balinteross additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT tamasleiner additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT zsoltszakacs additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials AT hussainalizadeh additionofdaratumumabtomultiplemyelomabackboneregimenssignificantlyimprovesclinicaloutcomesasystematicreviewandmetaanalysisofrandomisedcontrolledtrials
_version_	1718429252645289984

Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Ejemplares similares